计算溶液所需的质量、体积或浓度。
| 活性类型 | Relation | Activity value | Units | Action Type | 期刊 | PubMed Id | doi | Assay Aladdin ID |
|---|
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| B413378-1mg |
1mg |
现货 ![]() |
| |
| B413378-5mg |
5mg |
现货 ![]() |
| |
| B413378-10mg |
10mg |
现货 ![]() |
| |
| B413378-25mg |
25mg |
现货 ![]() |
| |
| B413378-50mg |
50mg |
现货 ![]() |
| |
| B413378-100mg |
100mg |
现货 ![]() |
| |
| B413378-250mg |
250mg |
现货 ![]() |
|
| 别名 | 巴洛沙韦酯 |
|---|---|
| 英文别名 | F0001-1475 | S033188 | S-033188 | {[(3R)-2-[(2S)-12,13-difluoro-9-thiatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.0^{3,8}]tetradeca-10,13-dien-11-yl]oxy}methyl methyl carbonate | baloxavir |
| 规格或纯度 | Moligand™, ≥97% |
| 英文名称 | Baloxavir marboxil |
| 生化机理 | 巴洛沙韦 marboxil 是一种帽子内切酶抑制剂,是一种抗病毒药物。 |
| 储存温度 | -20°C储存,充氩 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 聚合酶酸性蛋白抑制剂 |
| 产品介绍 |
Information Baloxavir marboxil Baloxavir marboxil, a cap-endonuclease inhibitor, is an antiviral drug. In vivo Single-dose oral baloxavir marboxil is well tolerated, had a favorable safety profile, and has favorable pharmacokinetic characteristics, including a long half-life, supporting single oral dosing. In nonclinical studies, baloxavir marboxil is a prodrug and is converted to an active form, baloxavir acid, by hydrolysis. After single oral administration in rats and monkeys, plasma concentrations of baloxavir marboxil are below the lower limit of quantification (LLOQ) at all sampling points, and area under the plasma concentration-time curve of baloxavir acid increased dose proportionally. The major excretion route of radioactivity is via fecal excretion, whereas urinary excretion was low in rats and monkeys. Baloxavir marboxil has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents. In murine models of seasonal influenza and avian influenza A(H5N1) or A(H7N9), orally administered baloxavir is associated with rapid reductions in pulmonary viral loads and decreased mortality. |
| ALogP | 2.602 |
|---|---|
| Rotatable Bond | 6 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| PubChem SID | 504772997 |
|---|---|
| 分子类型 | 小分子 |
| IUPAC Name | [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate |
| INCHI | InChI=1S/C27H23F2N3O7S/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23/h2-9,21,23H,10-14H2,1H3/t21-,23+/m1/s1 |
| InChi Key | RZVPBGBYGMDSBG-GGAORHGYSA-N |
| Canonical SMILES | COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F |
| Isomeric SMILES | COC(=O)OCOC1=C2C(=O)N3CCOC[C@H]3N(N2C=CC1=O)[C@H]4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F |
| PubChem CID | 124081896 |
| 分子量 | 571.55 |
| 溶解性 | Solubility (25°C) In vitro DMSO: 100 mg/mL (174.96 mM); Ethanol: 7 mg/mL (12.24 mM); Water: Insoluble; |
|---|---|
| DMSO(mg / mL) Max Solubility | 100 |
| DMSO(mM) Max Solubility | 174.962820400665 |
| Water(mg / mL) Max Solubility | <1 |
| 分子量 | 571.600 g/mol |
| XLogP3 | 3.800 |
| 氢键供体数Hydrogen Bond Donor Count | 0 |
| 氢键受体数Hydrogen Bond Acceptor Count | 12 |
| 可旋转键计数Rotatable Bond Count | 6 |
| 精确质量Exact Mass | 571.122 Da |
| 单同位素质量Monoisotopic Mass | 571.122 Da |
| 拓扑极表面积Topological Polar Surface Area | 123.000 Ų |
| 重原子数Heavy Atom Count | 40 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1090.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| Purity(HPLC area) | 97-100(%) |
|---|---|
| NMR Spectrum 1H | Conforms to structure |
| 1. Ivashchenko AA, Mitkin OD, Jones JC, Nikitin AV, Koryakova AG, Ryakhovskiy A, Karapetian RN, Kravchenko DV, Aladinskiy V, Leneva IA et al.. (2020) Non-rigid Diarylmethyl Analogs of Baloxavir as Cap-Dependent Endonuclease Inhibitors of Influenza Viruses.. J Med Chem, 63 (17): (9403-9420). [PMID:32787099] |
| 2. Takashita E, Morita H, Ogawa R, Nakamura K, Fujisaki S, Shirakura M, Kuwahara T, Kishida N, Watanabe S, Odagiri T. (2018) Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil.. Front Microbiol, 9 (3026). [PMID:30574137] |
| 3. Abraham GM, Morton JB, Saravolatz LD. (2020) Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza.. Clin Infect Dis, 71 (7): (1790-1794). [PMID:32020174] |